Moreover, diminished hepatic expression of ZO-1 found in HCC patients further confirms that targeting ZO-1 possibly provides a rational approach to the management of HCC and may serve as a marker for future molecular phenotyping of HCC. The gene discussed is TJP1; the disease is hepatocellular carcinoma.